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Introduction
Worldwide, tuberculosis is the most common serious opportunistic infection among people with HIV 
infection. The World Health Organization estimates that of  the 8.7 million individuals who developed 
incident tuberculosis in 2011, 1.1 million, or 13%, were co-infected with HIV.2 Further, of  those who suffer 
tuberculosis-related mortality, 31% are HIV-infected. Despite the complexities of  simultaneously treating two 
infections requiring multidrug therapy, antiretroviral therapy is life-saving among patients with tuberculosis 
and advanced HIV disease.4-7 
Timing of initiation of antiretrovirals among patients with HIV 
requiring tuberculosis treatment. 
There is now clear evidence that providing antiretroviral therapy to HIV-infected adults during tuberculosis 
treatment, rather than waiting until completion of  tuberculosis therapy, reduces mortality, particularly 
among those with advanced HIV disease. In one randomized controlled clinical trial among HIV-infected 
adults in South Africa, initiating antiretroviral therapy during tuberculosis therapy rather than waiting 
until tuberculosis treatment was completed reduced the hazard of  all-cause mortality by 56% and was 
beneficial regardless of  CD4 count.3 Subsequent clinical trials evaluating the optimal timing of  initiation of  
antiretroviral therapy during tuberculosis treatment were conducted.4-7 Results from these trials, all of  which 
were conducted in high prevalence/low resource settings, indicated that earlier initiation of  ART significantly 
reduced mortality in persons with (non-meningitis) HIV-TB and CD4 cell count below 50/mm3. Based on 
the results of  these trials, the Department of  Health and Human Services and Infectious Diseases Society of  
America now recommend that antiretroviral treatment be started two weeks after initiation of  tuberculosis 
treatment for most patients with CD4 counts less than 50 cells/mm3.8 
Challenges of co-treatment of HIV and tuberculosis. 
Concurrent treatment of  tuberculosis and HIV is complicated by 
•	 the adherence challenges of  polypharmacy, 
•	 overlapping side effect profiles of  antituberculosis and antiretroviral drugs,
•	  immune reconstitution inflammatory syndrome, and 
•	 drug-drug interactions.9 
The focus of  this document is the drug-drug interaction between rifamycin antibiotics (rifampin, rifabutin, 
and rifapentine) and four classes of  antiretroviral drugs: protease inhibitors, non-nucleoside reverse-
transcriptase inhibitors (NNRTI), CCR5-receptor antagonists, and integrase inhibitors.10, 11 Only two of  
the currently available antiretroviral drug classes, the nucleoside/nucleotide analogues (NRTI) [with the 
exception of  zidovudine 12, 13] and the entry inhibitor enfuvirtide (given parenterally)14 are free of  clinically-
significant interactions with the rifamycins. Although serum concentrations of  the NRTI zidovudine are 
diminished by co-administration of  rifamycins, no dose adjustment is recommended as the relationship 
between zidovudine plasma concentrations and efficacy is unclear.
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Objectives of these guidelines.
The purpose of  these guidelines is to provide the clinician with updated recommendations for managing the 
drug-drug interactions that occur when using antiretroviral therapy during tuberculosis treatment. (Table 1) 
Changes from previous versions of  these guidelines include: 
•	 a summary of  data from clinical trials regarding timing of  initiation of  antiretroviral therapy among 
patients with tuberculosis; 
•	 drug interaction data for new antiretroviral drugs; and 
•	 changes in dosing guidelines 
 » for rifabutin when co-administered with protease inhibitors, 
 » for nevirapine when co-administered with rifampin, and 
 » for raltegravir when co-administered with rifampin. 
•	 more detailed recommendations regarding co-treatment of  tuberculosis and HIV among children and 
pregnant women 
We include pharmacokinetic data as well as data about immunologic response and virologic suppression 
(where available) for antiretroviral drugs that are licensed and available for use in the United States when 
administered in combination with antituberculosis drugs.
Methodology for Preparation of these Guidelines 
These guidelines were developed by the HIV-TB Drug Interaction Guideline Development Group (hereafter, 
Guideline Development Group). The Guideline Development Group consisted of  experts in tuberculosis 
and HIV treatment and pharmacokinetics from CDC and other institutions (see listing of  the Guideline 
Development Group at the end of  this document on page 15). Members of  the Guideline Development 
Group were selected by the chair and co-chairs. They sought to include as members some persons who 
had participated in preparation and review of  the prior version of  these guidelines. Particular effort was 
made to include staff  from the U.S. National Institutes of  Health (NIH), in order to coordinate these 
recommendations with those of  the Federally-approved HIV/AIDS medical practice guidelines available 
online at http://www.aidsinfo.nih.gov/. No members of  the Guideline Development Group were deemed 
to have substantial competing interests related to the recommendations in these guidelines. Guideline 
Development Group member competing interests are listed on page 16.
A literature search was conducted to extract articles that met the following inclusion criteria: clinical studies 
involving healthy volunteers or patients with HIV or HIV/TB co-infection with relevant PK, safety, or HIV 
(viral load suppression, change in CD4 count) endpoints. Our search strategy was as follows: (1) between 
March 2011 and May 2012 we searched in Pubmed and Embase for English and French articles published 
from 1990 to 2012. We used as MeSH terms “tuberculosis,” “HIV,” and the names of  the drugs being 
evaluated. (2) After articles were extracted and selected, we hand-searched references at the end of  included 
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articles, and we searched trials listed at www.clinicaltrials.gov. (3) We reviewed abstracts from meetings 
(International AIDS Conference; International AIDS Society conference; Conference on Retroviruses and 
Opportunistic Infections; World Lung Health Conference; Workshop on Clinical Pharmacology of  TB 
Drugs) at which data from HIV and/or TB clinical trials are commonly presented; these were included if  
they met the inclusion criteria cited above; most of  these abstract reports had not yet completed the process 
of  peer review and publication . (4) We reviewed package inserts for included drugs specifically looking for 
drug interaction data. Articles and abstracts were screened and selected using the inclusion criteria. One 
hundred seventeen articles and abstract met the inclusion criteria and were included in the body of  evidence. 
These are included in the list of  referenced articles and abstracts at the end of  this document. The body of  
evidence was not graded for quality.
The chair of  the Guideline Development Group reviewed the previous version of  these guidelines  
(at http://www.cdc.gov/tb/publications/guidelines/TB_HIV_Drugs/default.htm), and then reviewed the 
references accumulated through the search strategy and inclusion criteria described above. The chair then 
drafted an updated revision of  the guideline, which was reviewed and discussed with the two Guideline 
Development Group co-chairs. Agreed revisions were made, and the revised document was then submitted to 
the rest of  the members of  the Guidelines Development Group Each member of  the Guideline Development 
Group reviewed the revised guideline draft and provided written comments and suggested revisions. 
Final recommendations were developed by the Guideline Development Group; the strength of  each 
recommendation was not graded. In one instance where the Guideline Development Group’s view conflicted 
with that of  the product manufacturer, the chair and co-chairs of  the Guideline Development Group held two 
teleconferences with representatives of  the manufacturer, staff  of  NIH, and staff  of  the U.S. Food & Drug 
Administration (FDA), to share and discuss unpublished data underlying the different views [see Rifampin 
and Efavirenz, below]. 
Following this discussion, and with the concurrence of  NIH and FDA members, the Guideline Development 
Group chose to include the following clarification, which is quoted directly from the introduction to the 
U.S. adult AIDS treatment guidelines, where it was intended to address similar issues: “... the science 
[underlying this guideline] evolves rapidly, [and] the availability of  new agents and new clinical data may 
change therapeutic options and preferences. Information included in these guidelines may not be consistent with 
approved labeling for the particular products or indications in question, and the terms “safe” and “effective” may 
not be synonymous with the Food and Drug Administration (FDA)-defined legal standards for product approval. 
The guidelines are updated [periodically].... However, the guidelines cannot always keep pace with the rapid 
evolution of  new data in this field, and they cannot provide guidance for all patients. Clinicians should 
exercise clinical judgment in management decisions tailored to unique patient circumstances.”1 
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Recommendations
The Role of Rifamycins in Tuberculosis Treatment
Rifamycins are an essential part of successful tuberculosis treatment. 
Rifamycins play a key role in the success of  tuberculosis treatment. Therefore, despite the complexity of  
drug interactions between rifamycins and antiretrovirals, treatment of  HIV-related tuberculosis requires 
their co-administration. This should not be avoided by using tuberculosis treatment regimens that do not 
include a rifamycin or by withholding antiretroviral therapy until completion of  anti-tuberculosis therapy. In 
randomized trials, regimens without rifampin or in which rifampin was only used for the first two months 
of  therapy resulted in higher rates of  tuberculosis treatment failure and relapse.15, 16 Although efforts are 
underway to identify new sterilizing drugs that can prevent relapse as effectively as rifampin, there are 
currently no good substitutes for rifamycins. Therefore, patients with HIV-related tuberculosis should be treated 
with a regimen including a rifamycin for the full course of  tuberculosis treatment, unless the isolate is resistant to 
the rifamycins or the patient has a severe side effect that is clearly due to the rifamycins (Tables 1a and 1b). 
Frequency of rifamycin dosing
Patients with advanced HIV disease (CD4 cell count < 100 cells/mm3) have an increased risk of acquired 
rifamycin resistance if  treated with a rifamycin-containing regimen administered once-, twice-, or thrice-weekly, 
especially during the intensive phase (first 2 months) of therapy, when bacillary load is still quite high. 17-19 
Tuberculosis drugs, especially rifamycins, should be administered 5 to 7 days per week for at least the first 2 months of  
treatment to patients with advanced HIV disease.19a 
Predicting drug interactions involving rifamycins
Rifamycins are notorious for causing drug interactions because they induce (or upregulate) multiple drug 
metabolizing enzymes and drug transporters. Rifampin, for example, is a potent inducer of  cytochrome 
P450 enzyme 3A, the enzyme subfamily responsible for metabolizing a large proportion of  drugs currently 
on the market, as well as other cytochrome P450 enzymes. The rifamycins vary in their potential to induce 
cytochrome P450 enzymes, with rifampin and rifapentine being much more potent inducers than rifabutin. 
Rifampin also induces Phase II metabolizing enzymes, which are responsible for biotransformations such as 
glucuronidation and sulfation, as well as the efflux pump p-glycoprotein and other drug transporters. 
Induction of  these enzymes can lead to reduced plasma concentrations of  co-administered drugs that 
are substrates of  these enzymes. For example, since most of  the protease inhibitor and NNRTI classes of  
antiretrovirals as well as the CCR5 antagonist maraviroc are metabolized by CYP3A4, induction of  CYP3A4 
by rifampin can lead to reduced serum concentrations of  these antiretroviral drugs with the attendant risks 
of  HIV treatment failure and emergence of  antiretroviral drug resistance. Similarly, rifampin upregulates the 
synthesis of  UDP-glucuronosyltransferase 1A1, which is the enzyme that metabolizes integrase inhibitors, 
including raltegravir.20 Knowledge of  the metabolic pathway(s) of  a drug can help the clinician predict the 
likelihood of  a drug interaction with co-administered rifamycins. The magnitude and the clinical relevance of  
the interaction, however, usually must be determined experimentally in clinical studies. 
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Managing Drug Interactions with Antiretrovirals and RIFAMPIN
Rifampin and NNRTIs
In areas with high rates of  both tuberculosis and HIV, initial antiretroviral drug regimens usually include 
efavirenz or nevirapine in combination with NRTIs (often in fixed-dose combinations). Thus, drug-drug 
interactions involving rifampin and the NNRTIs are of  high importance in these settings. Furthermore, 
efavirenz-based therapy is a preferred option for initial antiretroviral therapy in developed countries because 
of  its potency, availability in a once-daily co-formulation with tenofovir and emtricitabine, and durability of  
efficacy in randomized clinical trials.1 
Rifampin and efavirenz
Initial studies evaluating the effects of  rifampin on efavirenz pharmacokinetics demonstrated a modest 
decrease in efavirenz concentrations,21-23 but subsequent prospective studies have failed to show statistically 
significant reductions in concentrations of  efavirenz during rifampin therapy.24 (Table 2) Further, there is 
significant inter-patient variability in the effect that rifampin has on efavirenz concentrations. In patients with 
certain genetic polymorphisms that result in slow metabolism of  efavirenz (e.g., CYP 2B6 516 G>T), high 
concentrations of  efavirenz are common, even among patients also taking rifampin.25-27
When given at the standard dose of  600 mg daily, the trough concentration of  efavirenz (which is the best 
predictor of  its virological activity) remains well above the concentration necessary to suppress HIV in vitro 
among the vast majority of  patients on concomitant rifampin.28, 29 More importantly, multiple cohort studies 
and a randomized controlled trial have shown that the standard adult efavirenz dose (600 mg daily) together 
with 2 NRTIs is well-tolerated and highly efficacious in achieving complete viral suppression among adults 
on concomitant rifampin-based tuberculosis treatment.30, 31 Furthermore, in certain populations, a higher 
dose of  efavirenz (800 mg daily) has been associated with high serum concentrations and neurotoxicity.32 
There is limited evidence that sub-therapeutic efavirenz concentrations may be more likely among patients 
who weigh more than 60 kilograms and who are taking standard-dose efavirenz together with rifampin;33, 34 
however, findings of  sub-therapeutic concentrations in such persons have not been consistent.25, 30 Recently, 
the FDA approved a revised label for Sustiva® (efavirenz). The revision recommends that, if  efavirenz is co-
administered with rifampin, then the dose of  efavirenz should be increased to 800 mg in patients who weigh 
over 50 kg. This recommendation is based on pharmacokinetic modeling using data from several trials. No 
prospective trial has shown a reduction in anti-viral treatment failure with this strategy, or an increase in 
failure without it, Moreover, few published studies have evaluated this increased efavirenz dose or compared 
the 600 mg and 800 mg dose among patients who weigh over 50 kg.21, 35 
Therefore, because of  its potency, simplicity, and proven clinical efficacy, use of  efavirenz 600mg with 2 NRTIs, along 
with rifampin-based tuberculosis treatment is the preferred strategy for co-treatment of  HIV and tuberculosis  
(Table 1a). Some clinicians may increase the dose of  efavirenz to 800mg in persons weighing >50kg. We 
consider that data are insufficient to support a definitive statement in this regard. 
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What if efavirenz cannot be used?
Alternatives to efavirenz-based antiretroviral treatment are needed for some patients with HIV-related 
tuberculosis who are taking rifampin. Efavirenz is often avoided during the first trimester of  pregnancy, some 
patients are intolerant of  efavirenz, and some are infected with NNRTI-resistant strains of  HIV. Additionally, 
efavirenz cannot be used in HIV-infected children under the age of  3 years because appropriate dosing has not 
been determined for that age group (see section: Children). Alternatives discussed below include other NNRTIs, 
protease inhibitors, triple and quadruple NRTI regimens, integrase inhibitors, and CCR5 antagonists.
Rifampin and nevirapine
Nevirapine is typically given to adults at a dose of  200 mg once a day for the first two weeks of  treatment 
(initiation) followed by 200 mg twice daily or 400 mg once daily (extended release formulation) (maintenance 
therapy). This dosing strategy (of  initiation followed by maintenance therapy) is used for two reasons: (1) 
nevirapine induces its own metabolism, and, in most cases, its concentrations decline with continued dosing; 
and (2) high initial nevirapine concentrations have been associated with toxicities, such as skin rash. In the 
U.S., initiation of  nevirapine-based antiretroviral treatment is not recommended for adult or adolescent 
patients with higher CD4 cell counts (> 400 cells/mm3 for men, > 250 cells/mm3 for women) because of  
increased risk of  severe hypersensitivity reactions, including hepatotoxicity.1 The World Health Organization, 
though, recommends nevirapine as an option for women with CD4 cell counts up to 350 cells/mm3.36 
Taking nevirapine-based antiretroviral therapy together with tuberculosis treatment is complicated both by 
pharmacokinetic interactions related to rifampin and by overlapping toxicities of  nevirapine and the first-line 
antituberculosis drugs, notably skin rash and hepatotoxicity. 
Several studies have found that rifampin reduces serum concentrations of  nevirapine by 20-55%.37-40  
(Table 1). Decreases in serum concentrations caused by rifampin raise concerns about the efficacy of  
nevirapine-based antiretroviral therapy during rifampin-based tuberculosis treatment. Fortunately, results 
from recent prospective studies provide information for dosing strategies that may be helpful in this situation. 
One study conducted in South Africa found that patients who initiated nevirapine-based antiretroviral 
therapy during tuberculosis treatment (200 mg once daily for two weeks, then 200 twice daily) had a nearly 
two-fold higher risk of  having a detectable HIV viral load after six months compared to those taking 
nevirapine who did not have tuberculosis.30 Those patients who were already on nevirapine at maintenance 
doses (200 mg twice daily) when they started tuberculosis treatment did not have a higher risk of  HIV 
virologic failure. This suggests that if  nevirapine is initiated when the patient has already been receiving 
rifampin-containing tuberculosis treatment, the lead-in period puts patients at risk of  virologic failure because 
of  suboptimal nevirapine concentrations during the first two weeks of  therapy. A pharmacokinetic study in 
Uganda confirmed that concentrations of  nevirapine were often subtherapeutic when patients were receiving 
either 200 mg once daily or 200 mg twice daily, together with rifampin-based tuberculosis treatment.41 
Among Thai patients with advanced HIV, virologic and immunologic responses to nevirapine-based 
antiretroviral therapy when given at a dose of  200 mg twice daily were similar for those receiving rifampin-
containing tuberculosis treatment and those who were not.42 However, in a head-to-head comparison of  
antiretroviral therapy containing nevirapine 200 twice daily versus efavirenz 600 mg once daily, 65% of  
patients taking nevirapine and 70% of  patients taking efavirenz had HIV viral loads less than 50 copies/mL 
after 48 weeks of  treatment, and rates of  hepatotoxicity were similar in the two groups.43 Similarly, among 
patients in India randomized to receive either nevirapine (200 mg once daily for 14 days followed by 200 
mg twice-daily) or efavirenz 600 mg daily together with rifampin-containing tuberculosis treatment, those 
receiving nevirapine were more likely to suffer virologic failure, severe toxicity, or death, and the trial was 
stopped early.44 Together, these data demonstrate that efavirenz is more effective and less toxic than nevirapine 
for HIV-TB patients receiving antiretroviral therapy and rifampin-containing tuberculosis treatment. However, 
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giving nevirapine twice daily with rifampin (with no once-daily lead-in phase) may be an alternative when 
efavirenz cannot be used. Increasing the maintenance dose to 300 mg twice daily may cause higher rates of  
hepatotoxicity.45 Drug interaction studies with rifampin and the new 400 mg once-daily extended release 
formulation of  nevirapine have not been performed, so this combination cannot be recommended. 
In light of  these recent findings, for patients already receiving rifampin-containing tuberculosis therapy, we 
recommend that if  nevirapine must be used,1 it should be initiated without the once-daily lead-in dosing. That is, 
ART should be initiated with twice-daily nevirapine dosing (adult dose, 200 mg twice daily) and twice-daily dosing 
should continue throughout co-treatment. Close monitoring of  adherence and plasma HIV RNA is warranted. 
Therapeutic drug monitoring, if  available, should be considered.
Rifampin and other NNRTIs
Rilpivirine, a second-generation NNRTI, was approved by the United States Food and Drug Administration 
in May of  2011 and is available as a fixed-dose combination with tenofovir and emtricitabine. Rifampin reduces 
rilpivirine AUC by 80% and trough concentrations by 89%, so the two drugs should not be co-administered.46 Rifampin 
is also predicted to substantially reduce the concentration of  etravirine, another second-generation NNRTI, 
though this interaction has never been tested.47 
Rifampin and protease inhibitors
Protease inhibitor-based antiretroviral regimens remain an important option for the treatment of  HIV 
infection. Unfortunately, when co-administered with rifampin, concentrations of  many standard-dose 
protease inhibitors are severely diminished (>90%) compromising HIV treatment efficacy.48-52 The Guideline 
Development Group did not find studies evaluating drug interaction involving rifampin and darunavir.   
Several pharmacokinetic studies have been conducted to evaluate either higher doses of  the protease 
inhibitor or higher doses of  the pharmacologic boosting agent, ritonavir, or both.49, 51, 53, 54 Two strategies 
for dosing boosted protease inhibitors together with rifampin have been evaluated: super-boosting (giving 
standard-dose protease inhibitor plus a higher-than-usual dose of  ritonavir) versus double dosing (doubling 
the dose of  both the protease inhibitor and ritonavir). While these strategies may result in adequate protease 
inhibitor concentrations,51, 55 several studies involving healthy volunteers have reported unacceptable rates of  
hepatotoxicity. 51, 56-58
 It is unclear if  HIV-infected patients with tuberculosis will have the same high rates of  hepatotoxicity as 
healthy HIV-uninfected volunteers when treated with super-boosted protease inhibitors (standard-dose 
protease inhibitors given together with high doses of  ritonavir) or double-dose protease inhibitor/ritonavir 
combinations. Clinical experience with these strategies has recently been growing as clinicians and treatment 
programs try to find ways to treat patients who have NNRTI-resistant HIV and require tuberculosis 
treatment.59 In a small study in South Africa among adults with HIV (but not tuberculosis) who were already 
taking standard-dose lopinavir/ritonavir 400mg/100mg twice-daily with suppressed viral loads, rifampin 600 
mg daily was started, and lopinavir/ritonavir dosing was gradually increased over two weeks to a maximum 
dose of  800mg/200mg twice-daily (double dose).55 Therapeutic lopinavir concentrations were achieved, and 
the regimen was relatively well-tolerated, though two of  twenty-one patients had grade 3 or 4 hepatotoxicity. 
These initial positive clinical and experimental experiences with double-dose lopinavir/ritonavir suggest that 
these regimens may be tolerable and effective among at least some patients with HIV-related tuberculosis, but 
prospective data to guide patient and dose selection are still limited. Higher-dose lopinavir/ritonavir should only 
be used with close clinical and laboratory monitoring for possible hepatotoxicity in cases where there is a pressing need 
to start antiretroviral therapy and no other antiretroviral drug options are available.
1  Due to intolerance of or resistance to efavirenz, pregnancy, or young age (see above)
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Rifampin and triple or quadruple nucleos(t)ide regimens 
Regimens composed entirely of  NRTIs are less effective than combinations of  two classes of  antiretroviral 
drugs (e.g., NNRTI + NRTI).60-63 For example, virologic suppression achieved with zidovudine and 
lamivudine combined with efavirenz is superior to that observed with zidovudine, lamivudine, and abacavir, 
regardless of  pre-treatment viral load.60 Similarly, among adults receiving zidovudine and lamivudine plus 
either abacavir or nevirapine, the nevirapine-based regimen results in better immunologic and virologic 
responses than the triple-NRTI regimen, particularly among those with baseline HIV viral levels > 100,000 
copies/mL.61, 62 A regimen of  zidovudine, lamivudine, and the nucleotide agent, tenofovir, has been reported 
to be effective among some patients on rifampin-based tuberculosis treatment.63 However, this regimen has 
not been compared to standard initial antiretroviral therapy (e.g., efavirenz + 2 NRTIs) among patients taking 
rifampin. Finally, a quadruple drug regimen of  zidovudine, lamivudine, abacavir, and tenofovir was reported 
to be as active as an efavirenz-based regimen in initial small trials,64, 65 but a subsequent larger study suggested 
that a quadruple nucleos(t)ide regimen of  tenofovir, emtricitabine, zidovudine, and abacavir was less active 
than tenofovir-emtricitabine plus either efavirenz or ritonavir-boosted atazanavir.66 While these regimens of  
nucleosides and nucleotides alone cannot be recommended as preferred therapy among patients receiving rifampin 
because they have not been rigorously evaluated, the lack of  predicted clinically-significant interactions between 
these agents and rifampin make them an acceptable alternative during tuberculosis therapy for patients with lower 
plasma HIV RNA levels (<100,000 copies/mL) who are unable to take NNRTIs.64, 67 However, among patients 
who have HIV that is known to be resistant to NNRTIs or who have failed a first-line regimen (but for whom 
resistance testing is not available), this strategy may be inadvisable because these patients are at high risk of  
having HIV with NRTI resistance mutations. 
Rifampin with integrase inhibitors: 
Raltegravir, the first-in-class integrase inhibitor, is increasingly being used in both treatment-naïve and 
treatment-experienced adults with HIV. In pharmacokinetic studies among HIV-uninfected healthy 
volunteers, rifampin decreased the trough concentrations of  raltegravir 400 mg twice daily by ~ 60%.68 
Doubling the dose of  raltegravir to 800 mg twice daily improved overall raltegravir exposures, but trough 
concentrations were still reduced by 53% when compared to raltegravir 400 mg twice daily without 
rifampin.68 However, in dose-ranging studies among patients with HIV infection, the antiviral activity of  
raltegravir 200 mg twice daily was very similar to the activity of  the licensed 400 mg twice-daily dose, 
suggesting that the drug can still be effective even at reduced concentrations.69 However, in a recent trial 
of  once-daily dosing (800 mg) versus twice-daily dosing (400 mg) among treatment-naïve adults with HIV, 
low raltegravir trough concentrations in the daily dosing arm (but not the twice-daily arm) were associated 
with virologic failure.70 Thus, given the reductions in trough concentrations when raltegravir is given with 
rifampin, it is recommended to double the dose of  raltegravir to 800 mg twice daily in adults taking rifampin for 
tuberculosis. Though there have not yet been published prospective studies evaluating this regimen, raltegravir 
800 mg twice-daily given with rifampin has been shown to be effective in some clinical reports.71, 72 Raltegravir 
doses of  800 mg twice-daily and 400 mg twice daily have been tested in a clinical trial among patients 
with HIV receiving rifampin-containing TB treatment.73 Pending the availability of  full trial results, this 
combination (of  raltegravir 800mg twice daily and rifampin-containing TB therapy) should be used with caution, 
particularly among patients with high HIV viral loads who are just beginning antiretroviral therapy. There is little 
clinical experience with use of  concomitant raltegravir and rifampin, and safety and tolerability have yet to 
be explored in larger trials. While awaiting efficacy data from the study evaluating double-dose raltegravir 
among patients with HIV and TB taking rifampin, clinicians may prefer to use rifabutin (where rifabutin is 
available). Elvitegravir co-formulated with cobicistat, tenofovir, and emtricitabine (Stribild™, or the “Quad” 
pill) was recently approved by the Food & Drug Administration. Stribild should not be given together with 
rifampin, as rifampin is expected to reduce concentrations of  both elvitegravir and cobicistat. 
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Rifampin and CCR5-receptor antagonists: 
Rifampin has substantial interactions with the CCR5-receptor antagonist, maraviroc. An increased dose 
of  maraviroc has been recommended to allow concomitant use of  rifampin and maraviroc,36 but there is 
no reported clinical experience with this combination. Additional clinical studies will be needed to further 
evaluate whether or not these new agents can be used among patients receiving rifampin-containing 
tuberculosis treatment.
Managing Drug Interactions with Antiretrovirals and RIFABUTIN
Until recently, rifampin was the only rifamycin available in many settings. Rifabutin, though, is now off-patent 
and available in many countries; access to this drug is rapidly expanding.74 Rifabutin taken at a dose of  300 
mg once-daily might be as effective for tuberculosis treatment as rifampin.75-79 Compared to rifampin, though, 
rifabutin has significantly less effect on drugs metabolized by cytochrome p450 3a enzymes;80 this may reduce 
the magnitude of  drug-drug interactions (Table 3). However, several issues have negatively influenced its 
clinical utility. First, cost and/or access have historically precluded its use in most countries with high rates 
of  HIV-related tuberculosis;74 this situation is now changing. Second, drugs that induce or inhibit CYP3A 
metabolizing enzymes can influence rifabutin concentrations leading to the need for rifabutin dose adjustment, 
which adds to the complexity of  co-treatment. Finally, if  a patient whose rifabutin dose was decreased to avoid 
drug interactions related to co-treatment with antiretroviral therapy subsequently stops taking the interacting 
antiretroviral drug (e.g., ritonavir), the resulting rifabutin concentrations can become sub-therapeutic, putting the 
patient at risk of  tuberculosis treatment failure or emergence of  rifamycin resistance. 
Rifabutin and protease inhibitors
Rifabutin has little, if  any, effect on the serum concentrations of  ritonavir-boosted protease-inhibitors. 
However, rifabutin concentrations are increased when rifabutin is taken together with protease inhibitors. 
To mitigate the risk for rifabutin-related toxicity (such as uveitis or neutropenia), the previous edition of  this 
guideline recommended giving rifabutin at a dose of  150 mg thrice-weekly to adults taking boosted protease 
inhibitors. While cohort studies have yielded favorable virological and immunological outcomes of  protease-
inhibitor-based antiretroviral therapy in the setting of  rifabutin-based tuberculosis treatment 17, 81 clinical 
evaluation of  the anti-tuberculosis efficacy of  that combination remains limited. Some studies suggest that 
rifabutin concentrations among patients are too low with rifabutin 150 mg given thrice-weekly.82, 83 
In a trial among adults co-infected with HIV and tuberculosis taking ritonavir-boosted lopinavir, a dose 
of  rifabutin 150 mg once daily was relatively well-tolerated and was more likely to achieve target rifabutin 
concentrations than thrice-weekly dosing of  150 mg.84 Given the risk of  acquired rifamycin resistance with low 
rifabutin concentrations,85 we recommend rifabutin at a dose of  150 mg daily when given with a boosted protease 
inhibitor in adults. 82, 84, 86 However, clinicians should recognize that there are limited safety data with this 
dose and combination, and it is unclear whether or not the increase in concentrations of  rifabutin and its 
metabolite resulting from this dose will lead to higher risk of  uveitis, neutropenia, or hepatotoxicity. Patients 
taking this combination should be monitored for rifabutin-related toxicities. 87 88
 In addition, therapeutic drug monitoring, if  available, is one method for verifying that the desired rifabutin 
concentrations have been achieved. Since rifabutin 150 mg once daily would be sub-therapeutic if  the patient 
stopped taking the protease inhibitor, adherence to the protease inhibitor should be assessed with each dose 
of  directly observed tuberculosis treatment. One convenient way to do so is to give a supervised dose of  a 
once-daily protease-inhibitor at the same time as the directly observed dose of  tuberculosis treatment. 
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Rifabutin and other antiretrovirals
Because efavirenz reduces the concentration of  co-administered rifabutin, rifampin is the rifamycin of  choice for 
patients taking efavirenz-based antiretroviral therapy. In a study that evaluated rifabutin concentrations among 
patients receiving rifabutin twice-weekly, increasing the rifabutin from 300 mg to 600 mg in patients taking 
efavirenz-based antiretroviral therapy resulted in concentrations that were similar to those achieved among 
patients taking rifabutin 300 mg without efavirenz.89 However, other rifabutin dosing frequencies, such as 
thrice-weekly or daily, have not been evaluated. 
Given that nevirapine concentrations may be diminished among patients taking rifampin-containing 
tuberculosis treatment, rifabutin may be an option for patients taking nevirapine-based antiretroviral treatment. In 
a pharmacokinetic study among patients receiving nevirapine at standard doses and rifabutin at 300 mg daily, 
neither drug significantly impacted the concentrations of  the other.90 Therefore, dose adjustment is unlikely to 
be necessary, although clinical evaluations of  the safety and efficacy of  this combination in larger numbers of  
patients are needed. 
Trough concentrations of  etravirine are reduced by 35% by rifabutin, and etravirine reduces rifabutin 
concentrations by 17%. These changes are unlikely to be clinically significant, so no dose adjustment is 
recommended.47 There is, however, limited clinical experience with this combination. Although overall 
raltegravir concentrations are not significantly affected by rifabutin, trough raltegravir concentrations are 
diminished modestly (by about 20%) when the two drugs are co-administered.91 Until additional data become 
available, we recommend using standard-dose raltegravir (400 mg twice daily) with rifabutin. Trough concentrations 
of  elvitegravir are reduced by 67% when cobicistat-boosted elvitegravir is given together with rifabutin, so co-
dosing of  these drugs is not recommended.92
Treatment of Latent TB Infection with Rifampin or Rifapentine
Treatment of  latent TB infection (LTBI) is increasingly advocated in persons with HIV co-infection. 
Recommended options include daily self-administered isoniazid 300 mg for 9 months (9H) or daily self-
administered rifampin 600 mg for 4 months (4R).93 Isoniazid is the clear preference for treating LTBI in a patient 
on drugs that have unfavorable interactions with rifamycins. No adjustment of  ART dosing is required with the 
9H regimen. Use of  4R would require the same dose adjustments as noted above for rifampin-based therapy of  
active TB disease. There are no published data on the use of  rifabutin for LTBI. The Guideline Development 
Group suggests that rifabutin should be used for LTBI only if  there is a compelling need for short-course 
treatment of  LTBI, and/or if  neither 9H nor 4R can be used. Recently a new regimen of  12 once-weekly 
doses of  isoniazid 900 mg plus rifapentine 900 mg administered as directly observed therapy (DOT) has been 
recommended for use in persons who are HIV-uninfected or in persons with HIV who are otherwise healthy 
and not receiving ART.94 There are no data yet regarding the magnitude of  induction of  metabolizing enzymes 
that would be expected with once-weekly rifapentine at the recommended dose for LTBI; a manufacturer-
sponsored study evaluating the effects of  both once-weekly and daily rifapentine on efavirenz is underway.  
Treating Pregnant Women with Tuberculosis and HIV Co-infection
Limitations in antiretroviral agents that can be used during pregnancy
A number of  issues complicate the treatment of  the HIV-infected pregnant woman on antiretrovirals who 
has active tuberculosis. Most importantly, the choice of  antiretroviral drugs among pregnant women is 
limited. Efavirenz is not generally recommended during the first trimester of  pregnancy because of  concerns 
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about potential teratogenicity, although recent data do not suggest an elevation in this risk.95-97 Furthermore, 
pregnant women have an increased risk of  severe toxicity from didanosine and stavudine and, therefore, 
this dual NRTI combination is not recommended.98 Women with CD4 cell counts > 250 cells/mm3 at 
the time that antiretroviral therapy is initiated have an increased risk of  nevirapine-related hepatotoxicity. 
Consequently, initiation of  NVP among women with CD4 cell counts > 250 cells/mm3 is not recommended 
in the United States, while World Health Organization guidelines allow for its use in women with CD4 
counts up to 350 cells/mm3.1,36, 99
Because of  concerns about potential fetal bone effects based on non-human primate data, tenofovir is 
considered an alternative rather than a preferred antiretroviral drug during pregnancy (unless chronic 
hepatitis B virus infection is also present).100 The pharmacokinetics and safety of  etravirine and maraviroc 
among pregnant women have yet to be established. In a small study of  HIV-infected pregnant women, 
raltegravir appeared to be safe, and drug concentrations during the third trimester among trial participants 
were similar to their postpartum concentrations.101 
The Department of  Health and Human Services Panel on Treatment of  HIV-Infected Pregnant Women and 
Prevention of  Perinatal Transmission provides detailed recommendations regarding use of  antiretroviral 
drugs in HIV-infected pregnant women (available at http://AIDSInfo.nih.gov).100 Antiretroviral drugs that 
are preferred in pregnancy include zidovudine, lamivudine, nevirapine, and ritonavir-boosted lopinavir. 
Alternative NRTIs include abacavir, didanosine, emtricitabine, stavudine, and tenofovir; alternative protease 
inhibitors include ritonavir-boosted atazanavir or saquinavir. Use of  efavirenz after the first trimester can be 
considered in special circumstances, such as if  an HIV-infected pregnant woman requires tuberculosis therapy 
with rifampin and nevirapine is not tolerated. If  efavirenz is continued postpartum, adequate contraception 
must be assured.
The effect of pregnancy on the pharmacokinetics of antiretroviral drugs
Pregnancy alters the pharmacokinetics of  a number of  drugs, including antiretrovirals.102 For nevirapine, the 
data are mixed, with some studies showing decreased concentrations in pregnant women and others showing 
similar pharmacokinetics in pregnant and nonpregnant women.103-106
Small sample sizes and highly variable intra-patient plasma concentrations complicate interpretation of  
these comparative pharmacokinetic studies.107 Pharmacokinetic and efficacy data for efavirenz in pregnancy 
are limited, but a study of  25 women receiving efavirenz during the third trimester and postpartum found 
standard dosing to be adequate.108 The concentrations of  ritonavir-boosted lopinavir are decreased during the 
latter stages of  pregnancy, and some recommend increasing the dose to 600 mg lopinavir/150 mg ritonavir 
twice daily during the third trimester of  pregnancy, while others think standard-dose lopinavir/ritonavir with 
appropriate monitoring is sufficient.109-113 Once-daily lopinavir-ritonavir is not recommended in pregnancy 
because there are no data to address adequacy of  drug levels. 
Treatment of HIV-related tuberculosis among pregnant women
There are no published data on the combined effects of  pregnancy and rifampin on antiretroviral drug concentrations 
and HIV treatment efficacy. With limited pharmacokinetic data and published clinical experience it is difficult 
to formulate guidelines for the management of  drug-drug interactions during the treatment of  HIV-related 
tuberculosis among pregnant women. There is clearly an urgent need for research in this arena. 
For women with a CD4 count less than 250 cells/mm3 receiving rifampin-based tuberculosis treatment, 
nevirapine-based HIV treatment could be used, but the optimal dose is not known.114 Pregnant women 
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already receiving nevirapine-based regimens can continue nevirapine regardless of  CD4+ cell count, as 
toxicity appears limited to those first initiating nevirapine-based therapy. Efavirenz-based therapy may be 
an option after the first trimester of  pregnancy. The quadruple nucleoside/nucleotide regimen (zidovudine, 
lamivudine, abacavir, and tenofovir) is an alternative, especially for women with high CD4+ lymphocyte 
counts who are receiving antiretroviral drugs for prevention of  perinatal transmission rather than for 
maternal health indications, though additional experience during pregnancy is needed. Rifabutin is classified 
as pregnancy class B by the United States Food and Drug Administration,115 and lopinavir/ritonavir with 
rifabutin is also a reasonable option. Pregnant women receiving both antiretroviral and anti-tuberculosis 
drugs should have HIV RNA levels monitored more frequently, and if  virologic response is less than 
expected, therapeutic drug monitoring or a change in regimen should be considered.
Treating Children with HIV-associated Tuberculosis
Special challenges related to treating children with HIV and tuberculosis
HIV-infected children in high-burden countries have very high rates of  tuberculosis, often with severe, life-
threatening manifestations (e.g., extensive pulmonary disease, disseminated disease, meningitis). Such children 
may also have advanced and rapidly-progressive HIV disease, so there are pressing reasons to assure potent 
treatment for both tuberculosis and HIV. In addition to the complexities raised by the drug interactions 
discussed above, treatment of  pediatric HIV-related tuberculosis has additional challenges. There are limited 
data on the absorption, metabolism, and elimination of  anti-tuberculosis drugs in children, particularly in very 
young children (< 2 years of  age). The World Health Organization has recently compiled pharmacokinetic and 
efficacy data for children and updated their treatment guidelines for pediatric tuberculosis.116 The new guidelines 
suggest that higher doses of  first-line tuberculosis drugs, including most notably isoniazid and rifampin, be used. 
Pediatric formulation and dosing guidelines for rifabutin are not available for children.
Some antiretroviral drugs are not available in liquid formulations (though increasingly, chewable and dissolvable 
tablets are becoming available for pediatric use), and there are limited pharmacokinetic data for many 
antiretroviral drugs among young children. NNRTI-based therapy is not recommended as preferred therapy for 
perinatally-infected infants under age 1 year, whether or not they were exposed to single-dose nevirapine as part 
of  maternal-child HIV transmission prophylaxis, because of  higher failure rates compared to those initiating 
ritonavir-boosted lopinavir-based therapy.117-120 This inability to use NNRTI-based antiretroviral therapy limits 
options for antiretroviral therapy among children less than 1 year of  age receiving rifampin-based tuberculosis 
treatment.(Tables 1b and 2b) More specifically, limited pharmacokinetic data in children younger than age 3 or 
who weigh less than 13 kg have shown that it is difficult to achieve target efavirenz trough concentrations in this 
age group, even with very high (>30 mg/kg) doses of  an investigational liquid formulation. Thus, efavirenz is 
not recommended for use in children younger than age 3 years at this time.
Rifampin and protease inhibitors for children with HIV and tuberculosis
There are emerging pharmacokinetic data and clinical experiences with protease-inhibitor-based antiretroviral 
therapy among children with HIV-related tuberculosis. Ritonavir alone should not be used as the protease 
inhibitor component of  antiretroviral therapy in children receiving tuberculosis therapy. 121 Ritonavir-boosted 
lopinavir, though, may be a reasonable option. Optimal dosing for ritonavir-boosted lopinavir in children 
with HIV-related tuberculosis is being explored. In one study, children treated with super-boosted lopinavir 
(ritonavir in addition to doses of  co-formulated lopinavir/ritonavir to achieve mg to mg parity of  ritonavir 
and lopinavir) while on rifampin-based tuberculosis treatment achieved serum concentrations of  lopinavir 
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comparable to those of  children treated with standard dose lopinavir/ritonavir in the absence of  rifampin.122 
In a separate study of  15 South African children, while oral clearance was higher among children on 
tuberculosis treatment receiving super-boosted lopinavir than among children receiving standard pediatric 
ritonavir-boosted lopinavir doses who were not taking tuberculosis treatment, trough concentrations were 
therapeutic in all children. 123 Retrospective studies suggest that virologic response among children receiving 
super-boosted lopinavir and rifampin appears to be similar to that of  children receiving standard-dose 
lopinavir/ritonavir without tuberculosis treatment. However, response to double-dose lopinavir plus rifampin 
appears to be inferior.124 125 The preferred antiretroviral regimen among children on rifampin-based tuberculosis 
treatment is super-boosted lopinavir plus appropriate NRTI drugs. Additional prospective studies are needed to 
evaluate whether or not the higher doses of  rifampin now recommended for children will affect the activity 
of  super-boosted lopinavir. Additional research will also be needed to determine whether or not double-dose 
lopinavir/ritonavir will be as efficacious among children receiving rifampin-containing tuberculosis treatment 
as super-boosted lopinavir.
Rifampin and NNRTIs for children with HIV and tuberculosis
Efavirenz and rifampin for children
In a small pharmacokinetic study conducted among South African children with a median age of  6 years, 
efavirenz concentrations were commonly subtherapeutic with standard weight-based dosing of  efavirenz, 
whether or not they were taking rifampin.126 However, among children age >3 years participating in a 
retrospective cohort study in South Africa, those receiving efavirenz-based antiretroviral therapy had high rates 
of  viral suppression whether or not they were taking concomitant rifampin-containing tuberculosis therapy.125 
Although more data are needed, use of  standard dose efavirenz-based antiretroviral therapy may be considered in 
children over age 3 years receiving concurrent rifampin-containing tuberculosis therapy when the recommended 
antiretroviral regimen with super-boosted lopinavir-ritonavir is not tolerated or contraindicated.127 Careful 
virologic monitoring to ensure that viral suppression is achieved is recommended. Therapeutic drug 
monitoring to evaluate efavirenz levels may be considered, if  available. Additional studies are required to 
determine the appropriate dose of  efavirenz in infants and young children. Furthermore, studies on efavirenz 
pharmacokinetics in older children receiving the higher dose of  rifampin recommended by the World Health 
Organization are needed. 
Nevirapine and rifampin for children
Data on the influence of  concomitant rifampin on nevirapine levels in HIV-infected children are very limited. 
Substantial reductions in nevirapine concentrations were observed in a pharmacokinetic study in 21 Zambian 
HIV-infected children with tuberculosis treated with nevirapine, stavudine, and lamivudine antiretroviral 
therapy and receiving concurrent rifampin-based tuberculosis treatment.128 No studies were found of  
increased nevirapine dosing in children receiving rifampin-containing tuberculosis therapy. Therefore, there 
are insufficient data to recommend use of  nevirapine-based antiretroviral therapy in children receiving rifampin. 
Rifampin and triple nucleos(t)ide regimens for children with HIV and tuberculosis
The triple nucleoside regimen of  zidovudine, lamivudine, and abacavir has been suggested for young 
children who are taking rifampin-based tuberculosis treatment.129 However, there is limited published clinical 
experience with this regimen among young children with HIV, with or without concomitant tuberculosis. 
Furthermore, young children often have very high HIV RNA levels, raising the concern for increased risk 
of  treatment failure with triple NRTI regimens. Until additional studies become available, and given the limited 
number of  treatment options available for young children with HIV and tuberculosis, the triple-nucleoside regimen 
is recommended as an alternative for children <3 years receiving rifampin-based tuberculosis treatment. 
14
Co-treatment of Multidrug-resistant Tuberculosis and HIV
Multidrug resistant tuberculosis (tuberculosis resistant to rifampin and isoniazid) is a growing public 
health threat and may be particularly lethal among patients infected with HIV.2 Although knowledge of  
the metabolic pathways of  some second-line drugs (e.g. ethionamide, cycloserine, para-amino salicylate) 
is incomplete because many of  these drugs were developed and licensed decades ago, it is believed (based 
on knowledge of  chemical structure, metabolic pathways, and/or metabolism of  related agents) that 
most of  these drugs do not have significant drug-drug interactions with antiretrovirals. The second-line 
aminoglycoside antituberculosis drugs (capreomycin, kanamycin, and amikacin) are primarily renally 
excreted as unchanged compounds and are unlikely to have metabolic drug interactions with antiretrovirals. 
Fluoroquinolones (like ofloxacin, moxifloxacin, or levofloxacin) are also unlikely to have significant drug 
interactions with antiretrovirals. Since patients with multidrug-resistant tuberculosis do not receive rifampin, 
the risk of  clinically-significant drug interactions is markedly reduced. However, overlapping toxicities such 
as nephrotoxicity, QT prolongation on the electrocardiogram, psychiatric side effects, and gastrointestinal 
intolerance may limit options for co-treatment of  HIV and multidrug-resistant tuberculosis. 
Limitations of these Guidelines
The limitations of  the information available for writing these guidelines should be noted. First, drug-drug 
interaction studies are often done among healthy HIV-uninfected volunteers. Such studies reliably predict 
the nature of  a drug-drug interaction (e.g., that rifampin decreases the serum concentrations of  efavirenz). 
In cases of  extreme interactions, such as that between rifampin and unboosted protease-inhibitors, data 
from healthy volunteers can be definitive. However, healthy volunteer studies seldom provide the needed 
data regarding tolerability, dosing, and pharmacokinetic variability to determine the optimal management 
of  an interaction in patients with HIV-related tuberculosis receiving multidrug therapy. In this update of  the 
guidelines we emphasize studies performed among patients with HIV-related tuberculosis, particularly those 
that evaluate HIV treatment outcomes (like virologic suppression or immunologic response to antiretrovirals) 
or tuberculosis treatment outcomes (such as treatment failure with emergence of  resistance, or relapse after 
antituberculosis treatment). Second, rates of  drug metabolism often differ markedly between individuals; 
part of  that variance may be due to genetic polymorphisms in drug-metabolizing enzymes. Therefore, drug 
interactions and their relevance may not be the same in genetically different populations. Third, we included 
in the body of  evidence studies that have been presented at international conferences but that have not yet 
completed the peer review process and been published. Fourth, it is very difficult to predict the outcome 
of  complex drug interactions, such as those that might occur when three drugs with CYP3A activity are 
used together (e.g., rifabutin, atazanavir and efavirenz). Therapeutic drug monitoring, if  available, may be 
helpful in such situations. Finally, while pharmacokinetic and efficacy data in pregnant women and children 
receiving tuberculosis drugs and antiretrovirals are limited, we highlighted key recent findings that shed light 
on management options in these populations. Our recommendations for these key special populations are 
based primarily on expert opinion. 
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at
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